Table 52, Summary of included studies. Comparison 51. Augmenting with buspirone versus bupropion - Further-line treatment

Warning: The NCBI web site requires JavaScript to function. more...

Study	Population	Intervention	Comparison	Details of inadequate response/treatment resistance	Comments
Trivedi 2006 RCT US	N=565 Mean age (years): 41.1 Gender (% female): 59 Ethnicity (% BME): 22 Baseline severity: HAMD 15.8 (less severe)	Buspirone 15-60mg/day (mean final dose 40.9 mg/day) + citalopram	Bupropion sustained release 200-400mg/day (mean final dose 267.5 mg/day) + citalopram	Inadequate response (without remission [HAMD>7]) to a mean of 11.9 weeks of citalopram therapy (mean final dose 55mg/day)	Treatment length (weeks): 6 Outcomes: Depression symptomatology endpoint Depression symptomatology change score Remission Response Discontinuation due to side effects

Study

Population

Intervention

Comparison

Details of inadequate response/treatment resistance

Comments

RCT

N=565

Mean age (years): 41.1

Gender (% female): 59

Ethnicity (% BME): 22

Baseline severity: HAMD 15.8 (less severe)

Buspirone 15-60mg/day (mean final dose 40.9 mg/day) + citalopram

Bupropion sustained release 200-400mg/day (mean final dose 267.5 mg/day) + citalopram

Inadequate response (without remission [HAMD>7]) to a mean of 11.9 weeks of citalopram therapy (mean final dose 55mg/day)

Treatment length (weeks): 6

Outcomes:

: BME: black and minority ethnic; HAMD: Hamilton depression scale; RCT: randomised controlled trial

Further-line treatment: Depression in adults: Evidence review D.

NICE Guideline, No. 222.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.